As far as regulatory incentives go, some are pursued more than others. The US Food and Drug Administration's (FDA) orphan drug exclusivity provisions, for example, have brought about a renaissance of ...

On Thursday, the public had the first chance to air their grievances about the FDA’s controversial Commissioner’s National ...

But from the get-go, the program has been plagued by confusion. Critics say the listed priorities are overly vague, the ...

The US Food and Drug Administration (FDA) is set to increase the fee it charges users of a special, transferable voucher meant to reward developers of tropical disease treatments with an expedited ...

The US Food and Drug Administration (FDA) will convene a public hearing intended to obtain feedback on its Commissioner's National Priority Voucher (CNPV) pilot programme, a framework that has ...

Since it was established nearly a year ago by the FDA, the Commissioner’s National Priority Voucher (CNPV) program has been steeped in controversy as a potential tool for government officials to curry ...

CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / March 24, 2026 / Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a clinical-stage biopharmaceutical company advancing elraglusib, a first-in-class, ...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, ...

In 2007 the US Congress created the priority review voucher program to encourage the development of drugs for neglected diseases. Under the program, the developer of a drug that treats a neglected ...